Joshua Fitch, Editor

Though an increased rate of sudden infant death syndrome (SIDS) occurred from 2019 to 2020, a recent study suggests the increase wasn’t directly related to the COVID-19 pandemic.

At 2 years post-pediatric epilepsy surgery, 72% of patients were seizure-free compared to 33% of medically-treated patients.

A multi-country survey revealed 50% of meningitis vaccination appointments were delayed or canceled amid the COVID-19 pandemic, highlighting the need for “urgent action” to maintain routine vaccination levels among children, according to survey authors.

Eric Rubenstein, PhD, assistant professor, Department of Epidemiology, Boston University School of Public Health, explains why continued data collection for public school students with disabilities that experience homelessness is crucial for better support and care in this population.

With concerns of potential Bacillus cereus contamination, Atovaquone oral suspension, USP 750mg/5mL has been voluntarily recalled by Camber Pharmaceuticals Inc.

Data pulled from 11 communities in the Autism and Developmental Disabilities (ADDM) Network demonstrate higher autism prevalence for children aged 8 years.

According to the study, maintaining modest residual beta cell function in newly diagnosed patients is associated with a lower risk of vascular complications and hypoglycemia. 

The North American Society for Pediatric and Adolescent Gynecology’s position statement to eliminate period poverty has acquired a recent endorsement from the American Academy of Pediatrics. 

Children treated after presenting spinal muscular atrophy (SMA) symptoms maintained all previously achieved motor milestones up to 7.5 years post-dosing.

Leniolisib is the first and only treatment approved in the United States for APDS, a rare primary immunodeficiency.

Pediatric patients with BRAF V600E low-grade glioma as young as 1 year can now be treated with dabrafenib plus trametinib following its FDA approval.

A recent survey from the C.S. Mott Children’s Hospital National Poll on Children’s Health revealed how addictive parents believe vaping is for children.

Recent data revealed a 110% increase in speech disorder diagnoses for children aged 0 to 12 years in 2022, compared to the pre-pandemic era.

In identical phase 3 trials, roflumilast demonstrated topline positive results, reducing itch in children and adults with mild to moderate AD.

In a phase 3 clinical trial, dupilumab met both its primary and key secondary endpoints, demonstrating efficacy as a potential treatment for atopic hand and foot dermatitis.

A study found that children with acute concussions could have less symptom burden with an earlier return to school.

According to a recently published study, identification of early initiation and quick escalation to high-intensity drinking in adolescents and young adults can increase screenings for these types of behaviors.

Results from a recent phase 3 clinical trial demonstrated topline safety and efficacy results for tapinarof cream, 1% (VTAMA; Dermavant) as a potential treatment for atopic dermatitis in patients 2 years and older.

The American Academy of Pediatrics recently released several tips to prevent medication poisoning in young children because of a rise in opioid-related poisonings from 2005 to 2018.

A recent report lists the pediatric mental health crisis as the top patient safety concern following increases in anxiety and depression among children.